– USA, CA – RxSight, Inc., an ophthalmic medical device company, today announced the appointments of Bob Palmisano, Robert Warner, and Julie Andrews to its Board of Directors effective as of the closing of IPO on August 3, 2021.
The three appointees joined directors Andy Corley, Dr. William Link, Juliet Tammenoms Bakker, and Dr. Ron Kurtz.
“We are excited to welcome Bob, Robert and Julie to the RxSight Board of Directors as we move forward as a public company focused on improving patient vision after cataract surgery. Their shared values and collective expertise across commercial operations, finance and strategy will play a crucial guiding role in the next phase of growth for RxSight®,” said Board Chair, Andy Corley.
Concurrent with the new appointments, the Company announced the resignations of four long-serving board members Dr. Bruce Robertson, Dr. Daniel Schwartz, Christopher Cox, and Rick Wolfen.
Andy Corley added: “We also would like to thank Dr. Robertson, Dr. Schwartz, Mr. Cox, and Mr. Wolfen, each of whom has been critical to the successful growth and transition of RxSight from a developmental stage company to a commercial-stage company that is now transforming cataract surgery by giving doctors and patients the ability to customize their vision to fit their needs.”
About Bob Palmisano
Mr. Palmisano served as President and CEO of Wright Medical Group, Inc. from 2011 to 2020, ev3 Inc. from 2008 to 2010, IntraLase Corp. from 2003 to 2007, and Summit Technology Inc. from 1997 to 2000. Mr. Palmisano serves as Chairman of the Board of Priveterra Acquisition Corp. (Nasdaq: PMGMU) and previously served as the Chairman of the Board of Avedro, Inc., and on the boards of directors of Wright Medical Group Inc., ev3 Inc., IntraLase Corp., Osteotech, Inc., and Abbott Medical Optics, Inc., all publicly held companies, and Bausch & Lomb, a privately held company.
Mr. Palmisano holds a B.A. in Political Science from Providence College.
About Robert Warner
Mr. Warner served as President and General Manager of Alcon Vision Care Franchise from 2015 to 2018 and as President, Alcon U.S., and Canada from 2012 to 2015. Mr. Warner was a member of the Alcon Executive Leadership Team for over 10 years and led the Alcon transition from Nestle to Novartis majority ownership. Mr. Warner currently serves on the board of directors of two private medical device companies, i-Lumen Scientific and as Chairman of EyeYon Medical, and is also a board member of GRACE, the Grapevine Relief, and Community Exchange.
Mr. Warner holds a B.S. in Chemistry from Pace University and an MBA from Rutgers University.
About Julie Andrews
Ms. Andrews served as SVP, Global Finance, as Chief Accounting Officer and in other leadership roles at Wright Medical Group, Inc. from 2012 to 2020. Before joining Wright Medical, Ms. Andrews spent 14 years at Medtronic, Inc., including serving as VP, Finance for Medtronic’s $3.5 billion Spine and Biologics business. Ms. Andrews is currently on the board of directors of Priveterra Acquisition Corp. (Nasdaq: PMGM), a healthcare-focused special acquisition corporation, and serves as the chair of its audit committee.
Ms. Andrews received a BS in Accounting from Indiana University NW.
About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens, RxSight Light Delivery Device, and accessories, is the first and only commercially available intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield technology, a revolutionary UV protection layer built into the lens.
For more information: https://www.rxsight.com/us
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
